TUC-S.R.L.
24.4.2024 09:36:30 CEST | Business Wire | Press release
TUC S.r.l., the Deep Tech Company known for TUC.technology, launches a fundamental evolution of its offer, TUC.tiny™. This mobility revolution comes with all the features at the base of the TUC.technology patent, issued in over 140 countries worldwide. A small jewel based on TUC's three technological pillars, mechanical structuring, electronic management and data exchange, designed to also interface with consumer electronics thanks to the integration of USB Type-C technology. TUC.tiny™ becomes the USB of Mobility, a solution that aims to reinvent the interaction between users and vehicles bringing together mobility and everyday life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424672317/en/
TUC dashboard (Photo: Business Wire)
A real blank canvas, which can be transformed and customized countless times thanks to TUC.tiny™ and TUC.technology™, flexibly adapting to every need and preference. With TUC's innovative patented technology, personal devices such as smartphones, tablets, speakers and voice automation systems can be securely integrated. At the same time, automotive-specific elements such as dashboards, switches for driving mode selection and climate control, navigation systems with integrated cameras, harmonize with accessories that can be used both in the car and at home, such as fragrance diffusers and ambient lights.
TUC S.r.l. is at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aims to simplify and revolutionize the concept of vehicles, from a defined product to a definable experience. Distinguishing itself for technological excellence at international level, TUC has achieved significant recognition. With the launch of TUC 3.0 in 2023, the company is setting new standards in the industry by partnering with leading global OEMs.
With TUC.tiny™ and its advanced interface – which includes physical fixing, electrical and data transfer connectivity – any device can be integrated into the modular design of the dashboard, making it immediately operational. This allows users to customize their mobile space with extreme ease and freedom. TUC.tiny™ is designed to support all everyday devices that have a USB Type-C connection. These can be integrated into TUC.tiny™ through a state-of-the-art module. The proposed solution stands out for its ability to blend harmoniously into any part of the vehicle, both inside and outside, ensuring direct and simple installation, both in the production phase and after-sales, eliminating the need to adopt inefficient and unsafe solutions such as suction cups or other impractical and unreliable systems. In addition, the robustness of TUC.tiny™ is ensured by a mechanical or electro-actuated locking system, which introduces the novelty of security offered by NFC technology for reliable control of locking and unlocking functions.
"We are proud of the results achieved thanks to our constant commitment over the last few years," comments Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny™ represents our promise for the future; A vision of a world where technology and mobility come together in personalized experiences, designed around the needs of everyone. With TUC.technology®, we enable a paradigm shift, giving vehicle manufacturers tools to simplify development, engineering, and manufacturing, while enabling new business models that enhance continuous post-production customization. Our goal is that it is not the user who adapts to the life cycle of the vehicle, but that the vehicle can evolve to meet the changing needs of its user. We are thrilled with the results obtained by customers who are experimenting and adopting our technology, testifying to the validity and effectiveness of our work – continues Campana – This is the future that TUC S.r.l. is building: a mobility ecosystem where every innovation is guided by the values of democratization of technology, customization and sustainability, with the ambition to overcome current boundaries and explore new possibilities for a more connected and sustainable society. responsible."
The introduction of TUC.tiny™ is the completion of TUC.technology's offering. It marks a step towards the "democratization" of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives. This isn't just a technological advance; is TUC's invitation to imagine and build together the future of mobility, a world where technology unites us, improving every aspect of our daily journey.
ABOUT TUC.technology
TUC S.r.l. is a Deep-Tech company at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aim to simplify and revolutionize the concept of the vehicle, from a defined product to a definable experience. Distinguishing itself for technological excellence at an international level, TUC has achieved significant recognition, including exhibitions at CES in Las Vegas at the National Automobile Museum and recognition from major newspapers.
With the launch of TUC 3.0, the company is setting new standards in the industry by partnering with leading global OEMs. Learn more at www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424672317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom